Morgan Stanley reiterated coverage on AlloVir with a new price target

1/18/22 8:50:59 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Morgan Stanley reiterated coverage of AlloVir with a rating of Overweight and set a new price target of $45.00 from $48.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ALVR

Date	Price Target	Rating	Analyst
12/26/2023	$17.00 → $1.00	Buy → Underperform	BofA Securities
12/22/2023		Outperform → Market Perform	Leerink Partners
12/22/2023		Overweight → Underweight	JP Morgan
12/22/2023		Overweight → Neutral	Piper Sandler
8/18/2023	$17.00	Buy	BofA Securities
2/10/2022	$32.00 → $30.00	Outperform	SVB Leerink
1/18/2022	$48.00 → $45.00	Overweight	Morgan Stanley
12/17/2021	$37.00 → $32.00	Outperform	SVB Leerink